Boniface, C.; Deig, C.; Halsey, C.; Kelley, T.; Heskett, M.B.; Thomas, C.R., Jr.; Spellman, P.T.; Nabavizadeh, N.
The Feasibility of Patient-Specific Circulating Tumor DNA Monitoring throughout Multi-Modality Therapy for Locally Advanced Esophageal and Rectal Cancer: A Potential Biomarker for Early Detection of Subclinical Disease. Diagnostics 2021, 11, 73.
https://doi.org/10.3390/diagnostics11010073
AMA Style
Boniface C, Deig C, Halsey C, Kelley T, Heskett MB, Thomas CR Jr., Spellman PT, Nabavizadeh N.
The Feasibility of Patient-Specific Circulating Tumor DNA Monitoring throughout Multi-Modality Therapy for Locally Advanced Esophageal and Rectal Cancer: A Potential Biomarker for Early Detection of Subclinical Disease. Diagnostics. 2021; 11(1):73.
https://doi.org/10.3390/diagnostics11010073
Chicago/Turabian Style
Boniface, Christopher, Christopher Deig, Carol Halsey, Taylor Kelley, Michael B. Heskett, Charles R. Thomas, Jr., Paul T. Spellman, and Nima Nabavizadeh.
2021. "The Feasibility of Patient-Specific Circulating Tumor DNA Monitoring throughout Multi-Modality Therapy for Locally Advanced Esophageal and Rectal Cancer: A Potential Biomarker for Early Detection of Subclinical Disease" Diagnostics 11, no. 1: 73.
https://doi.org/10.3390/diagnostics11010073
APA Style
Boniface, C., Deig, C., Halsey, C., Kelley, T., Heskett, M. B., Thomas, C. R., Jr., Spellman, P. T., & Nabavizadeh, N.
(2021). The Feasibility of Patient-Specific Circulating Tumor DNA Monitoring throughout Multi-Modality Therapy for Locally Advanced Esophageal and Rectal Cancer: A Potential Biomarker for Early Detection of Subclinical Disease. Diagnostics, 11(1), 73.
https://doi.org/10.3390/diagnostics11010073
